We are monitoring the impact of COVID-19 & Recession alarm on Europe Autoimmune Monoclonal Antibodies Market Get in touch with us for detailed analysis Know More
Share on

Europe Autoimmune Monoclonal Antibodies Market Research Report – Segmented By Source, Application, End User & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) – Industry Size, Share, Trends, Growth & Forecasts (2022 to 2027)

Published: January, 2022
ID: 1107
Pages: 145

Europe Autoimmune Monoclonal Antibodies Market Size (2022 to 2027)

The size of the Autoimmune Monoclonal Antibodies market in Europe is expected to reach USD 10402.05 million by 2027 from USD 7165.29 million in 2022, growing at a CAGR of 7.74% during the forecast period.

The autoimmune monoclonal antibodies market in the European region is projected to be driven by the increasing availability of low-cost biosimilar monoclonal antibodies. The goal of biosimilars is to reduce pharmaceutical costs and improve access to therapy to counteract rising healthcare costs and deal with patient and government economic pressure. Furthermore, industry companies are gradually realigning their portfolios and pursuing appealing inorganic expansion opportunities, which are more likely to enhance the market growth. The market is expected to increase because of a growing number of government activities and funding for clinical research of drugs used in the Covid-19 treatment.

Furthermore, the key growth factor for the monoclonal antibodies market in Europe is the increase in genomics research and development activities linked with the introduction of technologically advanced platforms such as next-generation sequencing. Furthermore, increased awareness of the uses of Monoclonal Antibodies therapy among patients and clinicians is expected to help market growth. The market in Europe is predicted to grow at a lucrative CAGR due to a strong product pipeline.

Monoclonal Antibodies interest is fuelled by more substantial balance sheets, liquid finance markets, and regionally favorable borrowing rates. Furthermore, the upgraded technology's low cost makes it an appealing option for performing Monoclonal Antibody research studies. These are well-known biologics expected to generate billion-dollar revenue for pharmaceutical corporations over the forecasted period.

Alternative therapeutic approaches and natural remedies are growing more popular in Europe, which is expected to have a negative impact on the autoimmune monoclonal antibodies market in this region. On the other hand, the European market is constrained by the significant cost and time needed in market discovery and development, as well as a rigorous regulatory framework. The outcomes of COVID-19 are having a negative impact on numerous economic sectors in economies across the continent and the possibility of a slowdown in European market growth. Furthermore, key manufacturing segments have suspended operations worldwide in reaction to government-issued lockdown restrictions and the discontinuation of public transportation services.

This research report on the European autoimmune monoclonal antibodies market has been segmented and sub-segmented into the following categories

By Source:

  • Murine
  • Chimeric
  • Humanized
  • Human

By Application:

  • Systemic Lupus Erythematosus
  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Transplant Rejection/Graft Versus Host Disease

By End-User: 

  • Hospitals/Clinics
  • Research Institutes
  • Diagnostic Laboratories

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

The rising acceptance of monoclonal antibodies in the region and the spread of cancer across Europe are projected to drive the market for monoclonal antibodies in Europe. According to the World Health Organization, cancer is becoming more common, with an estimated 4.2 million additional cases reported in the last few years. Some of the country's key players include AstraZeneca plc, Pfizer Inc., Sitryx Therapeutics Ltd., Orchard Therapeutics plc, and Mylan N.V. These companies use a variety of products releases, partnerships, and collaborations to expand their market share.

Germany was the largest market for autoimmune monoclonal antibodies in Europe in 2020, followed by the United Kingdom. Over the years, the fastest expanding market in the region has been human monoclonal antibodies. As personalized medicine trends rise, the focus on totally humanized cancer monoclonal antibodies is expected to grow. Furthermore, the growing availability of biosimilar versions of these pharmaceuticals in the region opens the way for more cost-effective monoclonal antibody therapy. Product launches, partnerships, and collaborations are all possible strategies that market participants might employ to improve their position.

Because of government assistance in infection control and management and well-established healthcare infrastructure, the U.K. monoclonal antibodies market is predicted to have the most significant share in the European market. Germany, on the other hand, is Europe's fastest-growing country. The increase in the incidence of lifestyle-related disorders and the expanding population contribute to market expansion.

KEY MARKET PLAYERS:

Companies playing a promising role in the Europe Autoimmune Monoclonal Antibodies market include GlaxoSmithKline plc (U.K.), AstraZeneca plc (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb (U.S.), Johnson & Johnson (U.S.), Innovent Biologics, Inc. (China), Takeda Pharmaceutical Company Ltd. (Japan), Amgen Inc. (U.S.), Biogen Inc.(U.S.), and UCB Company (Belgium).

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Source                    

                                5.1.1 Murine     

                                5.1.2 Chimeric  

                                5.1.3 Humanized             

                                5.1.4 Human     

                5.2 By Application                           

                                5.2.1 Systemic Lupus Erythematosus      

                                5.2.2 Rheumatoid Arthritis          

                                5.2.3 Multiple Sclerosis 

                                5.2.4 Transplant Rejection/Graft Versus Host Disease     

                                5.2.5 Others      

                5.3 End User                     

                                5.3.1 Hospitals/Clinics   

                                5.3.2 Research Institute

                                5.3.3 Diagnostic Laboratories     

6. Geographical Analysis                                              

                6.1 Europe                         

                                6.1.1 Introduction           

                                6.1.2 U.K             

                                6.1.3 Spain         

                                6.1.4 Germany 

                                6.1.5 Italy           

                                6.1.6 France      

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

                7.5 Key Trends in Monoclonal Antibodies Development                 

                                7.5.1 Targeted Therapies             

                7.6 Promising Monoclonal Antibodies in Pipeline                              

                7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Monoclonal Antibodies                   

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 GlaxoSmithKline plc (U.K.)                   

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 AstraZeneca plc (U.K.)                           

                9.6 Innovent Biologics, Inc. (China)                          

                9.4 Bristol-Myers Squibb (U.S.)                 

                9.5 Johnson & Johnson (U.S.)                    

                9.6 Innovent Biologics, Inc. (China)                          

                9.7 Takeda Pharmaceutical Company Ltd. (Japan)                             

                9.8 Amgen Inc. (U.S.)                     

                9.9 Biogen Inc.(U.S.)                      

                9.10 UCB Company (Belgium)                    

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures   

                10.4 New Product Launches                       

11.Expert Opinions                                         

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                

  1. Europe Autoimmune Monoclonal Antibodies Market By Region, From 2022 - 2027 (USD Million)
  2. Europe Autoimmune Monoclonal Antibodies Market By Source, From 2022 - 2027 (USD Million)
  3. Europe Murine Monoclonal Antibodies Market By Region, From 2022 - 2027 (USD Million)
  4. Europe Chimeric Monoclonal Antibodies Market By Region, From 2022 - 2027 (USD Million)
  5. Europe Humanized Monoclonal Antibodies Market By Region, From 2022 - 2027 (USD Million)
  6. Europe Human Monoclonal Antibodies Market By Region, From 2022 - 2027 (USD Million)
  7. Europe Autoimmune Monoclonal Antibodies Market By Application, From 2022 - 2027 (USD Million)
  8. Europe Systemic Lupus Erythematosus Market By Region, From 2022 - 2027 (USD Million)
  9. Europe Rheumatoid Arthritis Market By Region, From 2022 - 2027 (USD Million)
  10. Europe Multiple Sclerosis Market By Region, From 2022 - 2027 (USD Million)
  11. Europe Transplant Rejection/Graft Versus Host Disease Market By Region, From 2022 - 2027 (USD Million)
  12. Europe Other Applications Market By Region, From 2022 - 2027 (USD Million)
  13. Europe Autoimmune Monoclonal Antibodies Market By End User, From 2022 - 2027 (USD Million)
  14. Europe Hospitals/Clinics Market By Region, From 2022 - 2027 (USD Million)
  15. Europe Research Institute Market By Region, From 2022 - 2027 (USD Million)
  16. Europe Diagnostic Laboratories Market By Region, From 2022 - 2027 (USD Million)
  17. U.K. Autoimmune Monoclonal Antibodies Market By Source, From 2022 - 2027 (USD Million)
  18. U.K. Autoimmune Monoclonal Antibodies Market By Application, From 2022 - 2027 (USD Million)
  19. U.K. Autoimmune Monoclonal Antibodies Market By End User, From 2022 - 2027 (USD Million)
  20. Germany Autoimmune Monoclonal Antibodies Market By Source, From 2022 - 2027 (USD Million)
  21. Germany Autoimmune Monoclonal Antibodies Market By Application, From 2022 - 2027 (USD Million)
  22. Germany Autoimmune Monoclonal Antibodies Market By End User, From 2022 - 2027 (USD Million)
  23. France Autoimmune Monoclonal Antibodies Market By Source, From 2022 - 2027 (USD Million)
  24. France Autoimmune Monoclonal Antibodies Market By Application, From 2022 - 2027 (USD Million)
  25. France Autoimmune Monoclonal Antibodies Market By End User, From 2022 - 2027 (USD Million)
  26. Italy Autoimmune Monoclonal Antibodies Market By Source, From 2022 - 2027 (USD Million)
  27. Italy Autoimmune Monoclonal Antibodies Market By Application, From 2022 - 2027 (USD Million)
  28. Italy Autoimmune Monoclonal Antibodies Market By End User, From 2022 - 2027 (USD Million)
  29. Spain Autoimmune Monoclonal Antibodies Market By Source, From 2022 - 2027 (USD Million)
  30. Spain Autoimmune Monoclonal Antibodies Market By Application, From 2022 - 2027 (USD Million)
  31. Spain Autoimmune Monoclonal Antibodies Market By End User, From 2022 - 2027 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample